Stephen Williams, Associate Chief Medical Officer at The University of Texas Medical Branch, shared on LinkedIn:
“Proud to have served as Global Primary Investigator for SunRISe-2 and to represent The University of Texas Medical Branch on this important international trial advancing care for patients with bladder cancer presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium today in San Francisco.
Grateful for Andrea Necchi presenting, Shahrokh Shariat, and the extraordinary investigators, teams, and patients who made this work possible. Outstanding vision and leadership by Christopher Cutie and the entire Johnson and Johnson team!”
Title: Gemcitabine intravesical system (Gem-iDRS) in combination with cetrelimab (CET) versus chemoradiotherapy (CRT) in muscle-invasive bladder cancer (MIBC): SunRISe-2 final results.
Authors: Andrea Necchi, Stephen B. Williams, Phuoc Tran, Yohann Loriot, Mariaconsiglia Ferriero, Hernan Cutuli, Makito Miyake, Guenter Niegisch, Paul Nguyen, Siamak Daneshmand, Felipe Villacampa-Aubá, Wolfgang Jessner, Meggan Tammaro, Marietta Kashmer, Jenna Carcione, Monelle Tamegnon, Hussein Sweiti, Robert A. Somer, Sumeet Kaur Bhanvadia, Shahrokh F. Shariat
Read the Full Article.
Andrea Necchi: SunRISe-2 and the Future of Bladder-Sparing Strategies in MIBC
